Cefoxitin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1040131/Cv/1'> | ||
Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. See also [https://en.wikipedia.org/wiki/Cefoxitin Cefoxitin]. | Cefoxitin is a second-generation [[cephamycin]] antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. See also [https://en.wikipedia.org/wiki/Cefoxitin Cefoxitin]. | ||
[[7kcx]]. | Cefoxitin is a beta-lactam antibiotic which binds to penicillin binding proteins, or transpeptidases. By binding to PBPs, cefoxitin prevents the PBPs from forming the cross-linkages between the peptidoglycan layers that make up the bacterial cell wall, thereby interfering with cell wall synthesis. It is a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem). However, cefoxitin is a better substrate than imipenem for beta-lactamases.<ref name="a10">PMID:8477758</ref> | ||
<scene name='10/1040131/Cv/2'>S. aureus penicillin-binding protein 4 (PBP4) in complex with cefoxitin</scene> ([[7kcx]]). | |||
<scene name='10/1040131/Cv/4'>Cefoxitin binding site</scene>. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||